Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.48 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.47 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | IAPP | P10997 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | BID | P55957 | 3/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.40 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7249953 | 0.95 | ERN1 (0.47) | ERN1TRIM24TRIM33CA1CA2 | |
| SCHEMBL29210937 | 0.93 | BID (0.48) | ERN1TRIM24TRIM33CA1CA2 | |
| SCHEMBL6893190 | 0.89 | ERN1 (0.52) | ERN1TRIM24TRIM33CA1CA2 | |
| SCHEMBL9627639 | 0.83 | IAPP (0.42) | IAPPHTTNPC1HPGDMAPK1 | |
| SCHEMBL986041 | 0.82 | ERN1 (0.55) | ERN1TRIM24TRIM33CA1CA2 | |
| SCHEMBL70772 | 0.81 | HTT (0.59) | IAPPHTTNPC1HPGDMAPK1 | |
| SCHEMBL27464370 | 0.81 | LIPG (0.40) | ALDH1A1MEN1MAPTKMT2ABID | |
| SCHEMBL7397839 | 0.80 | TRIM24 (0.48) | ERN1TRIM24TRIM33CA1CA2 | |
| SCHEMBL23829701 | 0.79 | HPGD (0.42) | ERN1IAPPHTTNPC1HPGD | |
| SCHEMBL11452728 | 0.79 | ALDH1A1 (0.38) | ERN1CA1CA2IAPPHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1589136-A | Pharmaceutical and cosmetic compositions containing aromatic aldehydes bearing oxygen-containing groups | CUTANIX CORP (US) | 2005-03-02 | — | — | CN | claimed |
| US-20030157154-A1 | Compositions containing hydroxy aromatic aldehydes and their use in treatments | CUTANIX CORPORATION | 2003-08-21 | — | — | US | claimed |
| CN-102666461-B | Ring compound, its production method, radiation-ray sensitive composition and corrosion-resisting pattern formation method | MITSUBISHI GAS CHEMICAL CO.,INC. (JP) | 2015-09-30 | — | — | CN | disclosed |
| CN-102973417-A | Pharmaceutical and cosmetic compositions containing oxy group-bearing aromatic aldehydes | CUTANIX CORP | 2013-03-20 | — | — | CN | disclosed |
| CN-102666461-A | Cyclic compound, process for production thereof, radiation-sensitive composition, and resist pattern formation method | MITSUBISHI GAS CHEMICAL CO | 2012-09-12 | — | — | CN | disclosed |
| US-8044067-B2 | Isoquinolines as IGF-1R inhibitors | ANALYTECON S.A. (CH) | 2011-10-25 | — | — | US | disclosed |
| EP-1931636-B1 | ISOQUINOLINES AS IGF-1R INHIBITORS | ANALYTECON SA (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-7875631-B2 | e.g.1-(3,5-dichlorophenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline; to prevent and/or treat cancer and other abnormal cell growth, and metabolic as well as blood vessel proliferate disorders, in which uncontrolled expression of insulin-like growth factor-1 receptor is observed | ANALYTECON S.A. (CH) | 2011-01-25 | — | — | US | disclosed |
| CN-100590118-C | Novel style heterocyclic compound as insulin-like growth factors first type acceptor inhibitor | ANALYTECON SA | 2010-02-17 | — | — | CN | disclosed |
| US-20090099229-A1 | Isoquinolines as IGF-1R Inhibitors | ANALYTECON S.A (CH) | 2009-04-16 | — | — | US | disclosed |
| EP-1732898-B1 | TETRAHYDROISOQUINOLINE- AND TETRAHYDROBENZAZEPINE DERIVATIVES AS IGF-1R INHIBITORS | ANALYTECON SA (CH) | 2008-01-23 | — | — | EP | disclosed |
| US-20070129399-A1 | Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as igf-1r inhibitors | ANALYTECON S.A. (CH) | 2007-06-07 | — | — | US | disclosed |
| CN-1922147-A | Novel style heterocyclic compound as insulin-like growth factors first type acceptor inhibitor | ANALYTECON SA (CH) | 2007-02-28 | — | — | CN | disclosed |
| CN-1589136-A | Pharmaceutical and cosmetic compositions containing aromatic aldehydes bearing oxygen-containing groups | CUTANIX CORP (US) | 2005-03-02 | — | — | CN | disclosed |
| EP-1443915-A1 | PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING OXY GROUP-BEARING AROMATIC ALDEHYDES | Cutanix Corporation (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20030157154-A1 | Compositions containing hydroxy aromatic aldehydes and their use in treatments | CUTANIX CORPORATION | 2003-08-21 | — | — | US | disclosed |
| WO-2003043621-A1 | PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING OXY GROUP-BEARING AROMATIC ALDEHYDES | CUTANIX CORPORATION (US) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030157154-A1 | Compositions containing hydroxy aromatic aldehydes and their use in treatments | TYR, HRH1, HRH2 | ERN1 4830/4885TRIM24 3252/4885TRIM33 2340/4885 |
| US-20070129399-A1 | Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as igf-1r inhibitors | IGF1R, INSR, GPR119 | ERN1 2489/4885TRIM24 1952/4885TRIM33 3715/4885 |
| US-20090099229-A1 | Isoquinolines as IGF-1R Inhibitors | IGF1R, IGFBP1, IGF2BP1 | ERN1 1619/4885TRIM24 623/4885TRIM33 3200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.